(Total Views: 544)
Posted On: 07/02/2025 2:14:40 AM
Post# of 154873
Re: chazzledazzle #154801
SK said in the 2022 video we hired a major academic to run LL / ICI synergies
Sept 2024 letter:
I am pleased to announce that CytoDyn is working with a team of experts to resume the exploration of Triple-Negative Breast Cancer (“TNBC”), including colleagues from the University of Hawaii Cancer Center, MD Anderson Cancer Center, and the Pennsylvania Cancer and Regenerative Medicine Research Center. We will be working with this team in the coming months to design and conduct a preclinical TNBC study that will aim to confirm the mechanism of action of leronlimab in oncology and address the question of potential synergies with both antibody-drug conjugates and......** immune checkpoint inhibitors.
May 13th, 2025:
We have also amended our current colorectal cancer trial to ensure the prospective collection of PD-L1 data in a second type of solid tumor.”
Max posted comment -- ICI is option.
He can't say -- are dosing with ICI's, because we of course don't know who will / won't upregulate.
So "option" is for the treating physician decision.
We have that database of LL / ICI synergies
Excerpt of doctors oath --- do no harm.
Zero doubt ICI's will be administered. Hell, if im the doctor, i would even question leaving that off the table, due to now legally knowing the mTNBC results.
I read the actual NASH/MASH protocol, that dam thing is 90 pages long. Nothing even close to clinical.gov
This CRC trial is phenominal for humanity !!
Sept 2024 letter:
I am pleased to announce that CytoDyn is working with a team of experts to resume the exploration of Triple-Negative Breast Cancer (“TNBC”), including colleagues from the University of Hawaii Cancer Center, MD Anderson Cancer Center, and the Pennsylvania Cancer and Regenerative Medicine Research Center. We will be working with this team in the coming months to design and conduct a preclinical TNBC study that will aim to confirm the mechanism of action of leronlimab in oncology and address the question of potential synergies with both antibody-drug conjugates and......** immune checkpoint inhibitors.
May 13th, 2025:
We have also amended our current colorectal cancer trial to ensure the prospective collection of PD-L1 data in a second type of solid tumor.”
Max posted comment -- ICI is option.
He can't say -- are dosing with ICI's, because we of course don't know who will / won't upregulate.
So "option" is for the treating physician decision.
We have that database of LL / ICI synergies
Excerpt of doctors oath --- do no harm.
Zero doubt ICI's will be administered. Hell, if im the doctor, i would even question leaving that off the table, due to now legally knowing the mTNBC results.
I read the actual NASH/MASH protocol, that dam thing is 90 pages long. Nothing even close to clinical.gov
This CRC trial is phenominal for humanity !!
(17)
(0)
